Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands

Miedema, Carien J.; Kors, Wijnanda A.; Ten, W. E. Tjon A; Kimpen, Jan L. L.

doi:10.1097/00006454-200102000-00008

Cited by 46 publications

(34 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Stratification by type of virus shows that total costs of LRTI caused by RSV (€2772) were slightly higher than total costs of LRTI caused by the other pathogens (€2374-2597). Number of workdays lost due to hospitalisation of the child (1.5 days) is similar to the results published by Miedema and coworkers [14].…”

Section: Discussionsupporting

confidence: 89%

“…Focusing on the influenza cases, 65% of the total costs per influenza case were due to indirect costs. The number of workdays lost (0.5 days) in the office-based LRTI cases is comparable to results published by Miedema and co-workers for the Netherlands [14]. In this study, parents stayed at home on average 0.5 days in the two weeks before the child's hospital admission due to RSV infection.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany

Ehlken¹,

Ihorst

Lippert³

et al. 2005

Eur J Pediatr

View full text Add to dashboard Cite

Data on the economic burden of lower respiratory tract infections (LRTI) in young children are lacking in Germany. The objective of the cost-of-illness study was to estimate the economic impact of community-acquired LRTI and nosocomial LRTI as well as of infections due to respiratory syncytial virus (RSV), parainfluenza viruses (PIV) and influenza viruses (IV). The economic analysis is part of the PRIDE study, a prospective, multi-centre, population-based epidemiological study on the impact of LRTI in children aged 0 to 36 months in Germany. The analysis includes children with community-acquired infections (1329 cases treated as outpatients, 2039 cases treated as inpatients) and nosocomial infections (90 cases). Medical services consumed were generated by chart abstraction and parental expenses data by telephone interviews within four weeks after physician visit or hospitalisation. Costs were evaluated from following perspectives: third party payer, parent and society. Total costs for outpatient treatment are Euro 123 per LRTI case. Stratified by virus type, total costs per case are Euro 163 (RSV), Euro 100 (PIV) and Euro 223 (IV). Total costs per hospitalised LRTI case amount to Euro 2579. Stratified by virus type, total costs per case are Euro 2772 (RSV), Euro 2374 (PIV) and Euro 2597 (IV). Total costs per nosocomial case are Euro 2814. Economic burden due to LRTI is Euro 213 million annually. It is concluded that treatment of LRTI in children up to age three causes a considerable economic burden in Germany. Presented results are the first data describing the economic burden of LRTI in young children assessed by means of the incidence data for Germany. This cost-of-illness study provides basic data for further decision-making, focusing on the economic assessment of preventive strategies for RSV, PIV and IV infections.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 85%

Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany

Ehlken¹,

Ihorst

Lippert³

et al. 2005

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] Early childhood wheeze after RSV infection has a high prevalence, influences quality of life, and generates substantial health care costs. [8][9][10][11] The pathogenesis of recurrent wheeze after RSV infection is still poorly understood. Gern and Busse distinguished two nonexclusive relationships between RSV infection and wheezing.…”

mentioning

confidence: 99%

Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants

et al. 2013

View full text Add to dashboard Cite

“…Compared to the human capital method, the friction cost method conservatively estimates the productivity losses. It has been estimated that on average two parental workdays are lost as the result of an RSVrelated hospitalization [29]. An RSV-related GP visit leads to a loss of 0.25 workdays.…”

Section: Health-care Resource Use Productivity Losses and Correspondmentioning

confidence: 99%

Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands

Meijboom

Rozenbaum²,

Benedictus

et al. 2012

Vaccine

View full text Add to dashboard Cite

Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. t r a c tIntroduction: Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory illness in infants, infecting virtually every child before the age of 2 years. Currently, several Phase 1 trials with RSV vaccines in infants are ongoing or have been completed. As yet, no efficacy estimates are available for these vaccine candidates. Nevertheless, cost-effectiveness estimates might be informative to enable preliminary positioning of an RSV vaccine. Methods: A decision analysis model was developed in which a Dutch birth cohort was followed for 12 months. A number of potential vaccination strategies were reviewed such as vaccination at specific ages, a two-or three-dosing scheme and seasonal vaccination versus year-round vaccination. The impact of the assumptions made was explored in various sensitivity analyses, including probabilistic analysis. Outcome measures included the number of GP visits, hospitalizations and deaths, costs, quality-adjusted life years and incremental cost-effectiveness ratios (ICERs). Results: Currently, without vaccination, an annual number of 28,738 of RSV-related GP visits, 1623 hospitalizations, and 4.5 deaths are estimated in children in the age of 0-1 year. The total annual cost to society of RSV in the non-vaccination scenario is D 7.7 million (95%CI: 1.7-16.7) and the annual disease burden is estimated at 597 QALYs (95%CI: 133-1319). In case all infants would be offered a potentially safe and effective 3-dose RSV vaccination scheme at the age of 0, 1 and 3 months, the total annual net costs were estimated to increase to D 21.2 million, but 544 hospitalizations and 1.5 deaths would be averted. The ICER was estimated at D 34,142 (95%CI: D 21,652-D 87,766) per QALY gained. A reduced dose schedule, seasonal vaccination, and consideration of out-of-pocket expenses all resulted in more favorable ICER values, whereas a reduced vaccine efficacy or a delay in the timing of vaccination resulted in less favorable ICERs. Discussion: Our model used recently updated estimates on the burden of RSV disease in children and it included plausible utilities. However, due to the absence of clinical trial data, a number of crucial assumptions had to be made related to the characteristics of potential RSV vaccine. The outcomes of our modeling exercise show that vaccination of infants against RSV might be cost-effective. However, clinical trial data are warranted.

show abstract

Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands

Abstract: RSV infections necessitating hospitalization in a secondary care hospital have remarkable effects on parental expenses, parental absence from work and medical consumption. On top of the hospital-related costs 15% should be added for parental expenses and socioeconomic costs.

Cited by 46 publications

References 7 publications

Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany

Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany

Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants

Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands

Contact Info

Product

Resources

About